Loading cancer entity…
Loading cancer entity…
Clinical trials
62 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001465 | Study of the Disease Process of Lymphangioleiomyomatosis | recruiting | — | 2,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 |
| NCT01484236 | National Lymphangioleiomyomatosis Registry, France(RE-LAM-CE) | recruiting | — | 200 | Vincent COTTINOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05676099 | TSC Biosample Repository and Natural History Database | recruiting | — | 5,000 | National Tuberous Sclerosis AssociationOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT03304678 | Discovery of Sirolimus Sensitive Biomarkers in Blood | completed | Phase 2 | 33 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06160310 | Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | recruiting | — | 300 | David M. RitterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05467397 | Feasibility of [11C]Acetate-PET in LAM and TSC | active not recruiting | Phase 1 / Phase 2 | 7 | Brigham and Women's HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06889168 | Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)(LAMP-2) | recruiting | Phase 1 | 20 | Columbia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07304856 | Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex | recruiting | — | 80 | University of MilanOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02432560 | Safety and Durability of Sirolimus for Treatment of LAM(MIDAS) | recruiting | — | 600 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03150914 | Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial(MILED) | active not recruiting | Phase 3 | 60 | University of CincinnatiOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05727852 | Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases | enrolling by invitation | — | 400 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT01353209 | Letrozole for Lymphangioleiomyomatosis(TRAIL) | completed | Phase 2 | 17 | University of CincinnatiOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT00414648 | Efficacy and Safety of Sirolimus in LAM(MILES) | completed | Phase 3 | 89 | University of CincinnatiOTHER | 3 | Nov 2, 2023 | clinicaltrials |
| NCT02494570 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa(AMPECT) | completed | Phase 2 | 34 | Aadi Bioscience, Inc.INDUSTRY | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05323370 | Lymphangioleiomyomatosis, a Study on Cathepsin K(LAM-CAK) | completed | — | 19 | University Hospital, ToursOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05785052 | Biomarkers of Renal Cancer(BRC) | unknown | — | 1,000 | Biorek S.R.L.INDUSTRY | 2 | Mar 27, 2023 | clinicaltrials |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | terminated | — | 20 | CENTOGENE GmbH RostockINDUSTRY | 8 | Feb 10, 2023 | clinicaltrials |
| NCT03253913 | Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial(RESULT) | completed | Phase 2 | 25 | University of CincinnatiOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05625919 | A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | unknown | Phase 1 / Phase 2 | 54 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05617105 | Molecular Characterization of Perivascular Epithelioid Cell Tumors(PEComesCells) | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT03062943 | A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)(LAM) | completed | Phase 2 | 30 | IRCCS MultimedicaOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02325505 | Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma | completed | — | 200 | InCor Heart InstituteOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT00126672 | RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03817515 | Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation | approved for marketing | — | — | Aadi Bioscience, Inc.INDUSTRY | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05190627 | Effect of Loratadine in Lymphangioleiomyomatosis(LORALAM) | unknown | Phase 2 | 62 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT02484664 | COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC(COLA) | completed | Phase 2 | 12 | Brigham and Women's HospitalOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05087134 | Characterizing LAM With 11C-Choline PET/CT | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04388371 | Glutamine PET Imaging in LAM | completed | Phase 1 | 5 | Vanderbilt University Medical CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT00366509 | Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases | completed | — | 157 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04577937 | Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis | unknown | N/A | 15 | dr. Stefano NavaOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01059318 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | completed | Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 3 | Nov 19, 2020 | clinicaltrials |
| NCT03477149 | EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications(EASYX-1) | completed | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT02061397 | Safety of Simvastatin in LAM and TSC(SOS) | completed | Phase 1 / Phase 2 | 10 | University of PennsylvaniaOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT03131999 | LAM Pilot Study With Imatinib Mesylate(LAMP-1) | completed | Phase 1 / Phase 2 | 18 | Medical University of South CarolinaOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04184193 | Benefits of Pulmonary Rehabilitation in Patients With Severe Lymphangioleiomyomatosis (LAM) | completed | — | 58 | Schön Klinik Berchtesgadener LandOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT03916575 | PEComas: Natural History and Prognostic Factors(PEComas) | unknown | — | 60 | University Hospital, Strasbourg, FranceOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00552955 | Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women | completed | — | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01687179 | Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis(SAIL) | completed | Phase 1 | 14 | Brigham and Women's HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT02859194 | The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients | completed | N/A | 10 | Yonsei UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials